DDInter1702 DDInter927
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Sorafenib {u} (Compound) treats {v} (Disease) liver cancer
Sorafenib {u} (Compound) binds {v} (Gene) BRAF
Sorafenib {u} (Compound) upregulates {v} (Gene) TSC22D3
Sorafenib {u} (Compound) downregulates {v} (Gene) MCM3
Sorafenib {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Sorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tacrine
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Sorafenib (Compound) resembles Vismodegib (Compound)
Sorafenib (Compound) treats liver cancer (Disease)
Sorafenib (Compound) binds BRAF (Gene)
Sorafenib (Compound) upregulates TSC22D3 (Gene)
Sorafenib (Compound) downregulates MCM3 (Gene)
Sorafenib (Compound) causes Hepatobiliary disease (Side Effect)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Sorafenib may lead to a major life threatening interaction when taken with Ibutilide